Inanovate has developed a revolutionary technology for the detection and measurement of multiple proteins called Longitudinal Assay Screening (LAS) for medical research and clinical diagnostics.
Inanovate began operations in 2007 with a mission to develop the best surface in the world for studying protein interactions. In 2008 the Company opened research and development facilities in Research Triangle Park, North Carolina and built a strong core team combining over 50 years of life science technology development expertise. This team was further strengthened through a network of advisors, consultants, collaborators and partners, from leading clinical and industrial organisations.
In 2009 Inanovate completed development and testing of the i-Slide – a novel protein microarray surface/slide that helped improve the sensitivity of protein detection and measurement experiments. Inanovate subsequently initiated alliance partnerships with Harvard Medical School and Brigham & Women’s Hospital on the discovery and validation of protein biomarkers for prostate and ovarian cancer, leveraging the benefits of the i-Slide technology.
While undertaking these biomarker projects, Inanovate realized that the i-Slide only addressed one aspect of a much larger problem faced by researchers and clinicians interested in the detection and measurement of multiple proteins; and in early 2010 the concept of Longitudinal Assay Screening (LAS) was born. As such, in 2010 Inanovate re-focused its mission on the development of LAS as a complete solution to multiple protein detection and measurement; the result was a revolutionary new technology and Inanovate’s flagship product– The Bio-ID 400.